Objectives: To assess the incidence and economic implications of loss of treatment response among patients with Crohn's disease (CD) treated with infliximab maintenance therapy. Methods: This was a retrospective observational study of infliximab response and costs among patients with CD using a large health-care claims database. Patients with CD receiving infliximab maintenance therapy with an initial response were selected from the Integrated Healthcare Information Services claims database (1999)(2000)(2001)(2002)(2003)(2004)(2005). Patients' claim histories were used to identify patterns of response to infliximab treatment. Incidence of loss of response was estimated using Kaplan-Meier method. Annual total health-care and CD-related costs were estimated and adjusted for inflation to 2005 US dollars. Generalized linear model was used to assess the impact of loss of response on treatment costs.
Introduction
Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease of an unknown etiology. CD affects approximately 144 to 198 people per 100,000 in North America [1] . Its recurrent symptoms and complications can significantly impact patients' physical and emotional well-being, as well as prevent their maintenance of gainful employment over the course of a lifetime [2] . Therefore, CD imposes a significant economic burden on patients and health-care systems. The direct medical cost of treating CD in the United States was estimated to be more than $1.7 billion in 1996 [3, 4] , with surgery and hospitalizations accounting for more than half of that total [5] .
There are no curative medical or surgical interventions for CD. Clinical management has traditionally focused on treatment of acute episodes and maintenance of remission [6] . With varying degrees of safety and effectiveness, several types of drugs are commonly used for these purposes, including systemic corticosteroids, immunomodulators (i.e., azathioprine, 6-mercaptopurine), broad-based immunosuppressants (e.g., methotrexate), aminosalicylates, antibiotics, and biologic agents [7] .
Infliximab is a chimeric (i.e., human-murine) monoclonal antibody that binds with the proinflammatory cytokine tumor necrosis factor with a substantial degree of specificity and affinity, thereby neutralizing the bioactivities in the disease cascade of CD [8] . In the United States, infliximab was first approved by the Food and Drug Administration (FDA) on August 24, 1998 , for the treatment of moderately to severely active CD and was later approved for maintenance therapy on June 28, 2002 [9] .
According to the FDA-approved product label, infliximab was approved for "reducing the signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active Crohn's disease who have had inadequate responses to conventional therapy" [9] . In addition to CD, infliximab was also approved for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis [9] .
The recommended dose of infliximab for CD is 5 mg/kg given as an intravenous induction regimen at Weeks 0, 2, and 6 followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter (i.e., the fourth dose is administered at Week 14) for the treatment of adults with moderately to severely active or fistulizing CD. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Clinical trials have demonstrated the efficacy and safety of infliximab in inducing remission in some patients with CD [10] . Studies have also demonstrated that patients receiving infliximab may form antibodies to infliximab [11, 12] , which is "associated with an increased risk of infusion reactions and a reduced duration of response to treatment" [13] . It has been demonstrated that the presence of antibodies to infliximab in concentrations greater than 8.0 mg/ml before infusion was predictive of a shorter duration of treatment response and a higher risk of infusion reactions [13] .
Compared to other conventional drug therapies currently available for CD (e.g., systemic corticosteroids, 5-aminosalicylates, and immunomodulators), infliximab had a higher acquisition cost of $542.40 per 100-mg vial in mid-2006 based on Average Sale Price plus 6% [14, 15] . Based on the assumption of a stable dosage over time, studies have found that the annual cost of infliximab maintenance therapy can range from approximately US $16,422 to $45,944 per patient per year [16, 17] . Some economic studies have evaluated the relative cost-effectiveness of infliximab therapy compared to other conventional therapies. Results are mixed and appear to depend on the treatment population, as well as the particular modeling methods and assumptions used. Infliximab therapy was shown to be marginally cost-effective to not cost-effective compared with standard care [15, 18] . Most available economic evaluations of infliximab use modeling approach and therefore are sensitive to model assumptions [15, 18] .
Although clinical results of infliximab therapy are readily available, primary economic profiles of CD with infliximab therapy are scarce [19] . Furthermore, economic assessments of infliximab often neglect the consequences of upward dose adjustment, clinical safety monitoring, and adverse reactions on infusionrelated expenses and costs. According to A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT I), more than half of patients in the 5 mg/kg infliximab maintenance group lost response by 1 year [20] . In particular, despite a noted substantial incidence of loss of response to infliximab even with maintenance therapy, the corresponding economic consequences of loss of response have not been fully analyzed. This omission is more remarkable given that economic studies have found infliximab to be marginally cost-effective based on long-term clinical outcomes [18, 21] . As response is lost, the health-care costs of patients with CD may increase. The lack of understanding and illumination of the cost consequence of loss of response may have led to a substantially biased estimate of the costs of infliximab therapy. To address this issue, this study examined the incidence and economic impact of loss of treatment response among patients with CD treated with infliximab maintenance therapy.
Methods

Study Design
This study followed patients with CD with initial responses to infliximab maintenance therapy and investigated long-term treatment responses and the costs associated with the loss of response.
Patients in this study were identified from the Integrated Healthcare Information Services claims database (1999) (2000) (2001) (2002) (2003) (2004) (2005) . This US administrative claims database contains information for more than 13 million enrollees from more than 35 health plans. It contains information on patients' health plan eligibilities and enrollment records, as well as medical and outpatient pharmacy claims.
Patients were included in this study if they met all six of the following criteria: 1) the patient had at least two independent CD diagnoses (based on the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 555.xx); 2) all of the patient's infliximab infusion medical claims were associated with a diagnosis of CD; 3) the patient's first infliximab infusion date for maintenance therapy (i.e., index date) was between July 1999 and June 2004; 4) the patient was continuously eligible for at least 6 months before and 12 months after the index date; 5) the patient was on infliximab maintenance therapy (defined as a minimum of four consecutive infusions with no between-infusion intervals >12 weeks [infliximab infusion records were identified from medical claims with Healthcare Common Procedure Coding System (HCPCS) code J1745, infliximab 10 mg]); and 6) the patient did not have an outpatient pharmacy prescription of infliximab. The last criterion was applied because infliximab prescriptions filled at a pharmacy are rare-in the Integrated Healthcare Information Services database, only 2.8% (213 out of 7740) of infliximab users have any pharmacy prescription of infliximab. Also, pharmacy prescriptions of infliximab are excluded because pharmacy databases do not provide information on the disease indication for which the prescription is written. Therefore, it is impossible to determine whether an outpatient pharmacy prescription of infliximab is used to treat CD. Furthermore, pharmacy prescriptions of infliximab are usually filled at a fixed interval (usually every 3 months); this will not provide sufficient information to determine the dose used per infusion during this period and the frequencies of infusion during this period.
Patients who did not have an initial response were excluded from the study. To qualify as having an initial response, patients must not have had any of the following five indicators of lack of improvement from the first to the fourth infusion dates: 1) a CD-related surgery, defined as all surgical procedures related to the bowel, rectum, and anus as identified by CPT codes; 2) a diagnosis of a new fistula that did not appear in the 6-month preindex period; 3) an emergency room visit or a hospitalization with a diagnosis of CD; 4) an initiation of a new CD drug therapy that had not been used previously (including a biologic other than infliximab, aminosalicylates, immunomodulators, methotrexate, corticosteroids, or metronidazole and fluoroquinolone family antibiotics); and 5) an occurrence of upward dose adjustment of infliximab, defined as any increase in dose amount versus the second infusion dose, and/or an increase in dosing frequency (<7 weeks interval twice during therapy), beginning with the third infusion as noted by Ollendorf et al. [22] .
A lack of response to infliximab treatment would almost invariably lead to one or more of these five indicators being observed. If patients do not respond to infliximab therapy, they frequently develop a new fistula or require urgent care, invasive procedures, a new therapy, or dosage increases of infliximab. To this point, infliximab dosage increases are recommended for loss of response according to the prescribing information in the product label [20] . Similar indicators for loss of response to infliximab therapy were used in the Gauging Adalimumab Efficacy in Infliximab Nonresponders study, which was a randomized controlled trial based on an FDA-approved study design [23] . Again, only patients with none of the five indicators before the fourth infusion date were considered to have an initial response and were included in this study. The choice of requiring the fourth infusion is consistent with a recent CD clinical study that evaluated infliximab as part of a long-term treatment regimen trial (ACCENT II) that evaluated loss of response (where initial response was evaluated at Weeks 10 and 14) [15] .
For cost analysis, the study sample was restricted to patients with health insurance eligibility during the period starting from 6 months before the index date (baseline) to 12 months after the index date (Fig. 1) . The 6-month baseline period allowed for the characterization of patients' baseline medical and cost profiles and the 12-month period following index date were used to define treatment costs associated with loss-ofresponse status. To study loss of treatment response rate, patients were followed until any of the five indicators occurred or until the end of data availability (i.e., June 30, 2005, or end of insurance eligibility), whichever occurred first. The time to loss of response was defined as the time from the index date to the earliest occurrence of any of the five indicator events.
Analytical Methods
Demographics and baseline medical profiles for the patients who experienced a loss of treatment response within 1 year were compared to those of patients who did not experience a loss of response. Chi-square statistics were used to test the statistical significance for discrete variables between the two groups, and Wilcoxon rank tests were used to test changes in continuous variables.
Because patients may not have had 24 months of insurance eligibility following their index dates, the Kaplan-Meier survival method was used to estimate the 2-year rate of loss of treatment response. In addition to the overall loss-of-response rate, the occurrence rate for each of the five indicator events was estimated individually.
To study the economic implications of loss of response comprehensively, both total and CD-related medical costs during the year following the index date were estimated. Reported costs were reimbursement amounts, and professional service rates were standardized by major service types. Total health-care costs were all medical and pharmacy claims within this 1-year period. Medical services claims encompassed inpatient, outpatient, and emergency room visits, as well as services provided in other locations (e.g., home, ambulatory surgical centers, skilled nursing facilities, nursing homes, ambulances, rehabilitation facilities, and independent laboratories). CD-related costs were costs for medical claims with the presence of a CD diagnosis (ICD-9-CM code: 555.xx) and CD-related medication costs. CD-related costs also included infliximab infusion claims and all medical claims that occurred on the infusion date (to capture the total cost of infusion-related services). All costs were inflationadjusted to 2005 US dollars using the medical component of the US Consumer Price Indexes. Wilcoxon rank tests were used to test for differences in costs between patients who experienced a loss of response and patients who did not. In addition to comparing patients with loss of response to those without loss of response, we also examined the total medical costs and CD-related costs by each of the five indicators for lack of improvement descriptively.
A multivariate analysis was also conducted to examine the association between loss of response in total and CD-related health-care costs. Specifically, a generalized linear model with a log link function and gamma distribution was used. The model was able to control for confounding factors, including patient demographics, types of insurance, presence of comorbidities (e.g., rheumatoid arthritis, depression, hypertension, cardiovascular diseases, gastroesophageal reflux disease [GERD] , chronic obstructive pulmonary disease), venue of infusion (e.g., outpatient, physician office, inpatient, emergency room), prior medications used, and prior resource utilizations.
Results
A total of 378 patients with CD were treated with infliximab maintenance therapy. Of these, 116 patients had at least one of the five indicators of lack of improvement before the fourth infusion date. These 116 patients were considered to be lacking initial response and therefore were excluded from the study. The remaining 262 patients comprised the final study sample. By the end of 12 months following the first infliximab infusion, 141 (54%) patients experienced loss of treatment response.
Patient Demographics
The overall sample population had a mean age of 38.6 years and half were male ( Table 1) . The majority of patients (64.5%) received their index infusions in physicians' offices, and most of the remaining patients (28.6%) received their index infusions in hospital outpatient settings. Patients who lost response within 1 year generally shared similar demographic and comorbidity profiles at baseline to those who did not. At baseline, patients who did not lose treatment response within the first year were more likely to have had rheumatoid arthritis (7.4% vs. 2.1%, P = 0.04) and higher use of immunomodulators (i.e., azathioprine, 6-mercaptopurine) (55.4% vs. 41.1%, P = 0.02) than those who lost response within the first year. Corticosteroids were the most common prior/ concomitant medication, used by 65% (n = 171) of the study sample before the infliximab maintenance therapy, followed by aminosalicylates, by 60% (n = 158) of patients at baseline.
Incidence Rates of Loss of Response
The overall 2-year loss of infliximab maintenance treatment response rate for the study sample was 77% (Fig. 2a) , based on Kaplan-Meier estimates. Infliximab dosage escalation, initiation of new drugs, and CD-related urgent care (i.e., emergency room, inpa- 
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tient visits) were the most common indicators for loss of treatment response (Fig. 2b and Table 2 ). After 2 years, 44% of patients with CD experienced dosage escalations and 44% initiated new drug therapies. The rate of CD-related emergency room visits or inpatient hospitalizations after 2 years was 32%. The rate of CD-related surgeries was 20% and the rate of a new fistula diagnosis was 12% ( Table 2) .
Cost of Treatment
During the 6-month baseline period, patients who later lost treatment response and those who did not incurred similar total treatment costs (US $10,385 vs. $10,589, P > 0.05) (Fig. 3) . During the 12-month follow-up period, those who did not experience loss of treatment response incurred $24,532 in total costs, on average, whereas those who did experience loss of response incurred 36% greater mean total costs ($33,289). The cost difference ($8756) between the two groups was statistically significant (P < 0.001).
Similarly, patients who did not experience loss of response with infliximab treatment within 1 year incurred $19,506 in CD-related medical and pharmacy costs compared to $27,250, or 40% greater CD-related costs for patients who experienced loss of treatment response. The $7744 difference was also statistically significant (P < 0.001). Based on these results, 88% of the total cost difference ($8756) was CD related. Descriptive comparison results of total medical costs and CD-related costs by each of the five indicators for lack of improvement are shown in Table 3 . Total treatment costs and CD-related costs were generally higher among patients who had such indicators than those who did not have them. The costs were significantly higher among patients who had experienced a CD-related surgery, CD-related emergency department visit or hospitalization, or a new CD-related drug therapy than otherwise. In particular, patients with an emergency department visit or hospitalization had total and CD-related costs Regression results showed that factors influencing total health-care costs for patients with CD, as well as health-care costs incurred before the maintenance therapy, included loss of response to infliximab maintenance treatment, age, and comorbidities of cardiovascular disease and GERD (Table 4) . Loss of response to treatment was a significant driver of total healthcare costs. For the 1-year total health-care costs, the regression coefficient from the generalized linear model with log link function for the loss of response was 0.2545 (P < 0.001), which translated to 29% greater total health-care costs for those patients with CD who experienced loss of response within 1 year of Wilcoxon rank tests were used to test for differences in costs between patients who experienced a loss of response and patients who did not. *P < 0.01.
infliximab maintenance therapy versus those who did not. Similarly, loss of response to maintenance treatment was also a statistically significant factor for CD-related health-care costs for these patients (Table 5) . It was associated with 29.3% greater CD-related costs (P < 0.001, coefficient = 0.2571).
Conclusions
This study fills a gap in the infliximab treatment/health economics literature [24] by investigating two issues: 1) the incidence of loss of treatment response to infliximab maintenance treatment; and 2) the cost implications of this lost response. Although infliximab has emerged as a common treatment for moderate to severe CD, its long-term medical and economic benefits as maintenance therapy had remained unclear.
In this analysis, 77% of patients had lost treatment response to infliximab within 24 months. The three most commonly seen lack-of-improvement indicators were infliximab dosage escalation (44%), new medication therapy for CD (44%), and CD-related urgent care (i.e., emergency room, inpatient; 32%). This is especially significant in that surgery and hospitalization typically constitute most of the total treatment costs for patients with CD [5] . In addition, this study is likely to have underestimated the true extent of dosage escalation among patients treated with infliximab because the 44% point estimate excludes patients who experienced early-dosage escalation before the fourth infusion.
Comparing the baseline characteristics including patient demographics, comorbidities, prior drug therapy, and baseline resource utilization and costs, it appears that there were few differences between patients who lost response and those who did not lose response. The only two variables with significant differences (rheumatoid arthritis and immunomodulators) between the two groups showed that patients who lost response might have less severity at baseline. To further investigate this issue, we also presented the baseline costs by each indicator as shown in Table 3 . Except for CD-related emergency and hospitalization, none of the indicators were associated with higher baseline costs. Therefore, it appears that response to infliximab was not strongly associated with CD severity measured at baseline.
Earlier studies of infliximab therapy often underestimated the extent of the cost consequences of loss of treatment response. This study compared the total annual health-care and CD-related costs between subgroups of patients with CD with different treatment outcomes. Both descriptive and regression analysis results show that loss of response is associated with a one-third increase in both total and CD-related costs.
Infliximab is indicated for moderate to severe CD. The study sample includes patients with CD in Table 3 Total and CD-related costs by lack of improvement indicator managed care insurance plans that were treated with infliximab. Therefore, it represents a relatively severe side of the CD severity spectrum, which should be considered when interpreting the economic outcomes. In the absence of the CD activity index (CDAI), the gold standard for classifying CD severity, data regarding comorbidity, fistula, past drug use, and baseline resource utilization and costs were used to profile patient severity and were controlled in the regression models. Patients with moderate CD and those with severe CD may have different reasons of initiation of and response to infliximab therapy. As a limitation of this claims database study, we could not separate patients with moderate CD from the patients with severe CD. Further clinical research with CDAI is needed to further examine infliximab loss of response rate and economic outcomes stratified by baseline severity of CD. Another limitation of this study was that it used claims data to determine patients' clinical outcomes versus direct observation of clinical response measurements, which were not available. Rather, five proxy indicators of loss of response were used. Nonetheless, it is worth noting that the observed loss-ofresponse rate after 1 year (54%) is identical to the loss-of-response rate at Week 54 reported in the ACCENT I trial for the infliximab maintenance therapy group [11] . The benefit of using claims data is that claims allow for the evaluation of loss-ofresponse rates over a longer time period (e.g., 2 years) than was done in clinical trials. These data reflect real-world loss-of-response rates. In addition, claims data enable a reliable estimation of economic costs associated with long-term treatment response with infliximab therapy.
The results of this study indicate that loss of response was prevalent for US patients with CD who received infliximab maintenance therapy in a real-world setting. The economic consequences of loss of response or lack of sustained response to infliximab maintenance therapy present a significant source of treatment costs and should be explicitly considered in any economic evaluation of infliximab treatment of CD.
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